Summary of Study ST002901

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001805. The data can be accessed directly via it's Project DOI: 10.21228/M8D71D This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Study ID	ST002901
Study Title	Potential serum metabolite markers and predictive features of depressive-like behavior and effective fluoxetine treatment in chronically socially isolated rats
Study Type	Metabolomics
Study Summary	Metabolic perturbation has been associated with depression. To examine peripheral metabolome changes, untargeted metabolic profiling was employed in the serum of chronic social isolation (CSIS) rats, an animal model of depression, and/or chronic fluoxetine (Flx) treatment using liquid chromatography-high resolution mass spectrometry.
Institute	University of Luebeck
Department	Bioanalytic Core facility
Last Name	Inderhees
First Name	Julica
Address	Ratzeburger Allee 160, 23562 Luebeck
Email	julica.inderhees@uni-luebeck.de
Phone	+4945131012805
Submit Date	2023-10-02
Num Groups	4
Total Subjects	32
Num Males	32
Raw Data Available	Yes
Raw Data File Type(s)	mzML
Analysis Type Detail	LC-MS
Release Date	2024-08-14
Release Version	1

Select appropriate tab below to view additional metadata details:

Project:

Project ID:	PR001805
Project DOI:	doi: 10.21228/M8D71D
Project Title:	Potential serum metabolite markers and predictive features of depressive-like behavior and effective fluoxetine treatment in chronically socially isolated rats
Project Type:	Metabolomics
Project Summary:	Metabolic perturbation has been associated with depression. To examine peripheral metabolome changes, untargeted metabolic profiling was employed in the serum of chronic social isolation (CSIS) rats, an animal model of depression, and/or chronic fluoxetine (Flx) treatment using liquid chromatography-high resolution mass spectrometry.
Institute:	University of Luebeck
Department:	Bioanalytic Core facility
Last Name:	Inderhees
First Name:	Julica
Address:	Ratzburger Allee 160, Luebeck, Schleswig-Holstein, 23562, Germany
Email:	julica.inderhees@uni-luebeck.de
Phone:	+4945131012805
Contributors:	Drangana Filipovic, Julica Inderhees

Subject:

Subject ID:	SU003014
Subject Type:	Mammal
Subject Species:	Rattus norvegicus
Taxonomy ID:	10116
Age Or Age Range:	2.5 months
Weight Or Weight Range:	300 - 350g
Gender:	Male
Animal Housing:	Standard conditions
Animal Light Cycle:	12 hour light/dark cycle
Animal Inclusion Criteria:	Responsive to chronic social isolation and/or Fluoxetine treatment

Factors:

Subject type: Mammal; Subject species: Rattus norvegicus (Factor headings shown in green)

mb_sample_id	local_sample_id	Group	Treatment
SA315614	Sample_ISF_4	Chronic social isolation	Fluoxetin
SA315615	Sample_ISF_3	Chronic social isolation	Fluoxetin
SA315616	Sample_ISF_5	Chronic social isolation	Fluoxetin
SA315617	Sample_ISF_7	Chronic social isolation	Fluoxetin
SA315618	Sample_ISF_8	Chronic social isolation	Fluoxetin
SA315619	Sample_ISF_2	Chronic social isolation	Fluoxetin
SA315620	Sample_ISF_6	Chronic social isolation	Fluoxetin
SA315621	Sample_ISF_1	Chronic social isolation	Fluoxetin
SA315622	Sample_IS_3	Chronic social isolation	NaCl
SA315623	Sample_IS_2	Chronic social isolation	NaCl
SA315624	Sample_IS_1	Chronic social isolation	NaCl
SA315625	Sample_IS_4	Chronic social isolation	NaCl
SA315626	Sample_IS_5	Chronic social isolation	NaCl
SA315627	Sample_IS_7	Chronic social isolation	NaCl
SA315628	Sample_IS_8	Chronic social isolation	NaCl
SA315629	Sample_IS_6	Chronic social isolation	NaCl
SA315630	Sample_CF_4	Control	Fluoxetin
SA315631	Sample_CF_3	Control	Fluoxetin
SA315632	Sample_CF_2	Control	Fluoxetin
SA315633	Sample_CF_5	Control	Fluoxetin
SA315634	Sample_CF_6	Control	Fluoxetin
SA315635	Sample_CF_1	Control	Fluoxetin
SA315636	Sample_CF_8	Control	Fluoxetin
SA315637	Sample_CF_7	Control	Fluoxetin
SA315638	Sample_C_5	Control	NaCl
SA315639	Sample_C_4	Control	NaCl
SA315640	Sample_C_3	Control	NaCl
SA315641	Sample_C_6	Control	NaCl
SA315642	Sample_C_8	Control	NaCl
SA315643	Sample_C_1	Control	NaCl
SA315644	Sample_C_2	Control	NaCl
SA315645	Sample_C_7	Control	NaCl

Showing results 1 to 32 of 32

Showing results 1 to 32 of 32

Collection:

Collection ID:	CO003007
Collection Summary:	The rats were anesthetized with a mixture of ketamine/xylazine (120/16 mg/kg) (Richter Pharma ag/Bioveta), perfused with physiological saline and sacrificed by decapitation from 9.00 to 12.00h. Cardiac blood samples were collected, allowed to clot for 2 hours and centrifuged (at 2,000 g) for 10 min at room temperature. Serum supernatant was aliquoted, frozen and stored at -80°C until further analysis.
Sample Type:	Blood (serum)
Storage Conditions:	-80℃

Treatment:

Treatment ID:	TR003023
Treatment Summary:	A CSIS model was employed as previously described (Filipović et al., 2022b). At the onset of the experiment (week 0), rats (n = 50) were randomly divided into two groups: control (n = 20, housed in groups of up to four) and CSIS (n = 30, housed individually, with no tactile or visual contact). For the first 3 weeks, rats were not exposed to any additional experimental procedures. During the second 3-week period, half of each group of rats was treated daily with intraperitoneal (i.p.) Flx solution (15 mg/kg/day) (Control+Flx and CSIS+Flx); the remaining rats were administered daily i.p. injections of physiological saline solution (Control+Vehicle and CSIS+Vehicle).

Treatment ID:

TR003023

Treatment Summary:

A CSIS model was employed as previously described (Filipović et al., 2022b). At the onset of the experiment (week 0), rats (n = 50) were randomly divided into two groups: control (n = 20, housed in groups of up to four) and CSIS (n = 30, housed individually, with no tactile or visual contact). For the first 3 weeks, rats were not exposed to any additional experimental procedures. During the second 3-week period, half of each group of rats was treated daily with intraperitoneal (i.p.) Flx solution (15 mg/kg/day) (Control+Flx and CSIS+Flx); the remaining rats were administered daily i.p. injections of physiological saline solution (Control+Vehicle and CSIS+Vehicle).

Sample Preparation:

Sampleprep ID:	SP003020
Sampleprep Summary:	Thawed aliquots of rat serum (100 µL) were subjected to solvent extraction once each with 400 µL of cold methanol/acetone/acetonitrile (1/1/1, v/v/v), containing 2.5 µM Metabolomics Amino Acid Mix Standard (Cambridge Isotope Laboratories, Andover, MA, United States) and mixed for 15 min at 4°C at 1000 rpm (Thermomixer Eppendorf), vortexed for 10 secs, and afterwards incubated for 2 h at 20°C. The mixture was then centrifuged for 10 min at 14,000 rpm at 4°C. The collected supernatants were evaporated to dryness in a vacuum concentrator (SpeedVac Concentrator, ThermoFisher). The dry extracts were reconstituted in 50 µL of methanol/acetonitrile (1:1) and vortexed for 15 sec followed by centrifugation at 14,000 rpm for 10 min at 4°C. The supernatants were transferred to LC-MS vials, and LC-HRMS analysis was performed.

Sampleprep ID:

SP003020

Sampleprep Summary:

Thawed aliquots of rat serum (100 µL) were subjected to solvent extraction once each with 400 µL of cold methanol/acetone/acetonitrile (1/1/1, v/v/v), containing 2.5 µM Metabolomics Amino Acid Mix Standard (Cambridge Isotope Laboratories, Andover, MA, United States) and mixed for 15 min at 4°C at 1000 rpm (Thermomixer Eppendorf), vortexed for 10 secs, and afterwards incubated for 2 h at 20°C. The mixture was then centrifuged for 10 min at 14,000 rpm at 4°C. The collected supernatants were evaporated to dryness in a vacuum concentrator (SpeedVac Concentrator, ThermoFisher). The dry extracts were reconstituted in 50 µL of methanol/acetonitrile (1:1) and vortexed for 15 sec followed by centrifugation at 14,000 rpm for 10 min at 4°C. The supernatants were transferred to LC-MS vials, and LC-HRMS analysis was performed.

Combined analysis:

Analysis ID	AN004760
Analysis type	MS
Chromatography type	HILIC
Chromatography system	Thermo Dionex Ultimate 3000 RS
Column	SeQuant ZIC-HILIC (150 x 2.1mm,5um)
MS Type	ESI
MS instrument type	Orbitrap
MS instrument name	Thermo Q Exactive Orbitrap
Ion Mode	UNSPECIFIED
Units	Relative area

Chromatography:

Chromatography ID:	CH003592
Instrument Name:	Thermo Dionex Ultimate 3000 RS
Column Name:	SeQuant ZIC-HILIC (150 x 2.1mm,5um)
Column Temperature:	35°C
Flow Gradient:	isocratic step of 100% B for 3 min, 100% B to 60% B in 15 min, held for 5 min, returned to initial conditions in 5 min and held for 5 min.
Flow Rate:	0.5ml/min
Solvent A:	100% water; 5mM ammonium acetate
Solvent B:	95% acetonitrile/5% (water; 5mM ammonium acetate)
Chromatography Type:	HILIC

MS:

MS ID:	MS004506
Analysis ID:	AN004760
Instrument Name:	Thermo Q Exactive Orbitrap
Instrument Type:	Orbitrap
MS Type:	ESI
MS Comments:	Data acquisition with data-dependent MS2 scans (top 10) was performed. Metabolites were identified based on exact mass, retention time, fragmentation spectra and isotopic pattern. Compound Discoverer 3.1 was used for data processing.
Ion Mode:	UNSPECIFIED